Sapporo Medical Journal

Abstract : Prostate cancer patients often suffer castration-resistant prostate cancer (CRPC), resulting in high mortality rates. Few is still known regarding the factors affecting survival in CRPC patients. We aimed to evaluate PSA level and time to PSA nadir as a prognostic marker for survival in CRPC patients. This is an analytical retrospective study evaluating castration-resistant prostate cancer patients’ survival. Evaluated data included sex, age, initial PSA level, final PSA level, time to PSA nadir (TTN), time to CRPC progression (TTC), and survival status. There were 24 patients with CRPC included in this study. There is a significant difference (p<0.05) of initial PSA level between surviving patients (445,7 + 165,6 ng/mL) and patients who died (200.7 + 144.9 ng/mL). The association between TTN and TTC was also significant (R=0.737, p<0.05). The differences of PSA nadir level, TTN, and TTC between the groups were insignificant (p>0.05). There is a significant difference of initial PSA between surviving and non-surviving patients, whereas no notable differences are apparent in PSA nadir level, time to PSA nadir, and time to CRPC progression. However, there is an association between the time to PSA nadir and CRPC progression.